Alternative Splicing in the Ligand Binding Domain of Mouse ApoE Receptor-2 Produces Receptor Variants Binding Reelin but Not alpha 2-Macroglobulin*

Christian BrandesDagger , Larissa KahrDagger , Walter StockingerDagger , Thomas Hiesberger§, Wolfgang J. SchneiderDagger , and Johannes NimpfDagger

From the Dagger  Institute of Medical Biochemistry, Department of Molecular Genetics, Biocenter and University of Vienna, A 1030 Vienna, Austria and the § Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9046

Received for publication, March 26, 2001, and in revised form, April 4, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

LR7/8B and ApoER2 are recently discovered members of the low density lipoprotein (LDL) receptor family. Although structurally different, these two proteins are derived from homologous genes in chicken and man by alternative splicing and contain 7 or 8 LDL receptor ligand-binding repeats. Here we present the cDNA for ApoER2 cloned from mouse brain and describe splice variants in the ligand binding domain of this protein, which are distinct from those present in man and chicken. The cloned cDNA is coding for a receptor with only five LDL receptor ligand-binding repeats, i.e. comprising repeats 1-3, 7, and 8. Reverse transcriptase-polymerase chain reaction analysis of mRNA from murine brain revealed the existence of two additional transcripts. One is lacking repeat 8, and in the other repeat 8 is substituted for by a 13-amino acid insertion with a consensus site for furin cleavage arising from an additional small exon present in the murine gene. None of the transcripts in the mouse, however, contain repeats 4-6. In murine placenta only the form containing repeats 1-3 and 7 and the furin cleavage site is detectable. Analysis of the corresponding region of the murine gene showed the existence of 6 exons coding for a total of 8 ligand binding repeats, with one exon encoding repeats 4-6. Exon trapping experiments demonstrated that this exon is constitutively spliced out in all murine transcripts. Thus, the murine ApoER2 gene codes for receptor variants harboring either 4 or 5 binding repeats only. Recombinant expression of the 5-repeat and 4-repeat variants showed that repeats 1-3, 7, and 8 are sufficient for binding of beta -very low density lipoprotein and reelin, but not for recognition of alpha 2-macroglobulin, which binds to the avian homologue of ApoER2 harboring 8 ligand binding repeats.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

The low density lipoprotein receptor (LDLR)1 family consists of a growing number of structurally related composite cell surface receptors with partially overlapping ligand specificity (1, 2). For example, the LDLR harbors structurally and functionally defined modules, corresponding to distinct exons in the gene (3). These modules are as follows: (i) the "type A-binding repeats" (LA repeats) of ~40 residues each, displaying a triple disulfide bond-stabilized and negatively charged surface mediating receptor/ligand interactions; (ii) "type B repeats" (EG repeats), also containing six cysteines each; EG repeats are homologous to regions in the epidermal growth factor precursor; (iii) modules of ~50 residues with a consensus tetrapeptide, Tyr-Trp-Thr-Asp (YWTD); (iv) a so-called "O-linked sugar domain"; (v) a short transmembrane domain of ~20 amino acids; and (vi) the cytoplasmic region with a signal for receptor internalization via coated pits. LR7/8B (4, 5) and its human homologue called ApoER2 (6, 7) belong to the close relatives of the LDLR made up of exactly the same domains in the same order as in the LDLR. The occurrence of distinct splice variants adds yet another level of complexity to this family of proteins. LR7/8B expression in chicken is highly restricted to the brain, where the protein resides in large neurons and Purkinje cells, and in cells constituting brain barrier systems such as the epithelial cells of the choroid plexus and the arachnoidea and the endothelium of blood vessels (8). The finding that chicken LR8B acts as receptor for alpha 2-macroglobulin (8) suggests a role in the clearance of alpha 2-macroglobulin-proteinase complexes from the cerebrospinal fluid. Ligand binding studies with two splice variants of human ApoER2 demonstrated high affinity of the receptor to beta -VLDL, indicating that in mammals the receptor might be involved in apoE-mediated transport processes in the brain as well (7). This is an interesting aspect because a genetic link between certain alleles of the ApoE gene and the development of late onset Alzheimer's disease has been established (9). However, no differences in the splice variant patterns of ApoER2 between control and Alzheimer's patients exist (10).

Targeted disruption of the apoER2 gene alone or in combination with that for the VLDL receptor gene revealed a key function of both receptors during embryonic brain development (11). Absence of functional ApoER2 and VLDL receptor leads to an inversion of cortical layers and absence of cerebellar foliation. This phenotype is indistinguishable from that seen in animals carrying either a mutation in the reeler gene or in the disabled gene (for review see Refs. 12-14). Both ApoER2 and VLDL receptor bind reelin, which is secreted by Cajal-Retzius cells (15, 16), and do so apparently together with cadherin-related neuronal receptors (17) and/or alpha 3beta 1 integrin (18), which may act as co-receptors for reelin to transmit the signal into migrating neurons. Upon reelin stimulation the intracellular adapter protein disabled-1 (Dab1), which interacts with the cytoplasmic domains of apoER2 and VLDLR (19, 20), becomes tyrosine-phosphorylated (21, 22). These data suggest that ApoER2 and VLDL receptor directly relate the extracellular reelin signal into a cellular response via Dab1, leading to the ultimate cell responses required for the correct positioning of newly generated neurons during brain development.

In addition, interaction screens with apoER2 and other members of the receptor family have resulted in the identification of many other candidate proteins interacting with the cytoplasmic domains of the respective receptors, suggesting that they may be part of an intricate network of signaling pathways (23, 24).

Here we present the full-length cDNA and the partial characterization of the mouse apoER2 gene and show that differential splicing events in the ligand binding domain produce functional receptor variants that are distinct from those expressed in chicken and man. Splicing is tissue-specific and is regulated during brain development.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

5'-RACE Cloning of the Complete cDNA for Mouse ApoER2-- The 5'-end of the mouse cDNA for apoER2 was cloned by 5'-RACE using the MarathonTM cDNA amplification kit (CLONTECH) according to the manufacturer's protocol. First and second strand cDNA was synthesized from 5 µg of poly(A)+ RNA and the poly(A) synthesis primer provided by the kit. 5'-RACE was done in two successive rounds of PCR amplification, with the sense primer located in an adapter ligated to the cDNA. The antisense primer was located in the known sequence from a partial cDNA clone (4). The first round, which resulted in 334 bp of new sequence, was done using primer ASR1 (5'-CCGCTCCTGGTTGCACCGTTTGATG). The second round was performed with primer ASR2 (5'-GTCCTCGTCGCTGTTGTCCG) and resulted in additional 174 bp of new sequence exceeding the start codon.

cDNA Preparation and PCR Analysis-- Total RNA was produced from 200 mg of frozen tissue (total brain and placenta from mature female Balb/c mice, and total chicken brain from female Brown Derco) using TriReagent (Molecular Research Center, Inc.). Poly(A)+ RNA was prepared from 500 µg of total RNA using the Micro-Fast Track mRNA Isolation Kit (Invitrogen) according to the manufacturer's protocol. First strand cDNA synthesis was performed with 1 µg of poly(A)+ RNA and random hexamer primers using SuperScript Reverse Transcriptase (Life Technologies, Inc.). One-tenth of the cDNA was used for subsequent PCR in the presence of 1.5 mM MgCl2, 0.2 mM dNTPs, 2 units of Taq DNA polymerase (PerkinElmer Life Sciences), and 1 µM of the appropriate primers on a GeneAmp 2400 (PerkinElmer Life Sciences). PCR conditions are as follows: 5 min initial denaturation at 94 °C, 1 min denaturation at 94 °C; 1 min annealing (for specific annealing temperatures, see primers), and 1 min extension at 72 °C for 40 cycles. The following primers have been used (numbers of the primers refer to the respective primers shown in Fig. 2: mouse 1, 5'-CGAGAATGAGTTCCAGTGTGG; mouse 2, 5'-CGTGAAGATCAGAGATGGGC, 1/2 annealing at 60 °C; mouse 3, 5'-CTGCCGAGAAGTTAAGCTGC; mouse 4, 5'-CCGCTCCTGGTTGCACCGTTTGATG, 3/4 annealing at 58 °C; mouse 5, 5'-GAGTTCCAGTGCAGCAACCG; mouse 6, 5'-CCGCTGCGGCAGGTGAACTGG, 5/6 annealing at 60 °C; chicken 7, 5'-CCAAGCAAGTATGCCCAGC; chicken 8, 5'-TTGGACACAGCCTGCCTCG, 7/8 annealing at 57 °C. PCR products were analyzed by agarose gel electrophoresis. Bands were isolated from the gel using the QIAEX II gel extraction kit (Qiagen) and subcloned into the pCR2.1 vector (Invitrogen). Several clones from each fragment were isolated, and positive clones were identified by PCR analysis and sequenced.

Partial Characterization of the Mouse ApoER2 Gene-- A mouse ES P1 library (Genome Systems, Inc.) was screened by PCR using the following primer pair: A, 5'-TGTCTGCACAATAACGGCGGCTGTTC, and B, 5'-ACAGGTCTTCTGGTCCAAGAGCTGGAAG. PCR conditions are as follows: 2 min initial denaturation at 94 °C, 1 min denaturation at 94 °C, 1 min annealing at 56 °C, 1 min extension at 72 °C for 35 cycles. Using 1 µg of genomic DNA, a 105-bp amplicon derived from exon 9 (EG repeat A) was produced under these conditions. P1 plasmid DNA from positive clones was prepared from 150-ml cultures (Escherichia coli strain NS 3529, Genome Systems, Inc.) using the plasmid MidiKit (Qiagen) according to manufacturer's instructions including an additional phenol extraction step before loading on the column. P1 DNA was digested with BglII and shotgun-subcloned into the BamHI site of pBluescriptII (sK+). Clones were screened by PCR using two independent primer combinations (pair 1, 5'-GCGCGGACGGCGACTTCACC, 5'-GCCTTCGATTCGTCAGAGCC; pair 2, 5'-CCGCCGTCCACGCACTCGCC, 5'-CGAGAATGAGTTCCAGTGTGG) located within the 5'-part and the 3'-part of the ligand binding domain, respectively. The resulting clones were G14AS13 and 8AS-3.5 (see Fig. 3A). The rest of the gene covering the ligand binding domain of the receptor was covered by PCR clones derived from the undigested P1 clone with the following primer combinations (see Fig. 3A): 1, 5'-TGCAGCTTCAGCATCTCTCC and 5'-GTCCTCGTCGCTGTTGTCCG; 2, 5'-CCTTGGTGTGGAGATGCGATGAGG and 5'-AGGTGAGCATGGCGGCCTGCC; 3, 5'-GCGCGGACGGCGACTTCACC and 5'-GCAGCTTAACTTCTCGGCAGG; 4, 5'-GACGGAGAGAAGGACTGTGAGG and 5'-TGGTCCACTCAGTCAACCTGTCC; 5, 5'-AGTTCTATGAGAACTCATCCACC and 5'-GTGCTCATGACTTAGTGATGTGG; 6, 5'-AGTGGCGAGTGCGTGGACGGC and 5'-TGAGGTCAGTGCAGATGTGG. PCR products were isolated from the gel using the QIAEX II gel extraction kit (Qiagen), subcloned into the pCR2.1 vector (Invitrogen), and sequenced.

Exon Trapping Experiments-- For the exon trap experiment two constructs were made. One contained the exon coding for repeats 4-6 including 89 bp of the upstream and 563 bp of the downstream intron, respectively (corresponding to genomic clone 5, Fig. 3). For this, entire clone 5 was cloned into filled in SalI sites of the exon trap vector pet01 (MoBiTec GmbH, Göttingen) resulting in pEx4-6. The second construct contained genomic clone 5 plus clone G14A13B3 (see Fig. 3), thus harboring two exons, one for repeat 2 and the other for repeats 4-6. This construct (pEx2, 4-6) was made by cloning the entire genomic clone G14A13B3 into pEx4-6 upstream of clone 5 using XbaI and NotI sites in the polylinker of pet01. 3 µg of DNA was transfected into 293 cells using Lipofectin reagent (Life Technologies, Inc.), and cells were grown on a 90-mm plate. 48 h after transfection, cells were harvested, and mRNA was prepared using the Micro-fast track from Invitrogen. 1 µg of mRNA was taken and reverse-transcribed using 1 µl of Superscript (Life Technologies, Inc.) and the cDNA primer provided by the exon trap kit. RT-PCR was performed using 1/10th of the cDNA reaction using two primers from the exon trap kit (5'-primer 2 and 3'-primer 3) located 5' and 3' of the insert of pet01, respectively. PCR products were analyzed on a 1.5% agarose gel and sequenced.

Expression of Chicken LR8B and Mouse ApoER2Delta 4-6 and ApoER2Delta 4-6,8-- Chicken LR8B and mouse apoER2Delta 4-6 and apoER2Delta 4-6,8 were expressed in the human embryonic kidney cell line 293. The full-length cDNA of mouse apoER2Delta 4-6 and apoER2Delta 4-6,8 were assembled by joining a partial cDNA for the mouse protein (4) with the appropriate PCR products derived from mouse brain cDNA with primers 5RS1 (5'-GGAGCCCCGGGCCCGCTATGG) and 5RAS6 (5'-GCTCATCAATGAGGACCACC) via an internal BglII site. The products of the PCR reaction with 5RS1, 5RAS6 containing repeats 1-3, 7, and 8 and repeats 1-3 and 7 were purified on a 1% agarose gel, cloned into pCR2.1, and sequenced. The partial cDNA (see above) was cloned into the eukaryotic expression vector pCI-Neo. In order to produce the full-length cDNAs, fragments containing 4 repeats and 5 repeats were cut out from the pCR2.1 constructs via an internal BglII and the XhoI site (present in the polylinker of pCR2.1) and cloned into the pCI-Neo construct containing the rest of the cDNA. The construct used for expression of chicken LR8B in 293 cells has been described (8). Transfection of the cells was performed using Lipofectin Reagent (Life Technologies, Inc.) according to the manufacturer's protocol. Stable transformants were selected by the addition of 500 mg/liter G418 to the medium (Dulbecco's modified Eagle's medium (Life Technologies, Inc.), 10% fetal calf serum, 584 mg/liter glutamine).

Preparation of Cell Extracts, Electrophoresis, and Western Blotting-- Total cell extracts from 293 cells expressing LR8B, ApoER2Delta 4-6, or ApoER2Delta 4-6,8 were prepared as described for chicken embryo fibroblasts (25). Electrophoresis, transfer to nitrocellulose membranes, and Western blotting were performed as described previously (26). The polyclonal antibodies against the cytoplasmic domains of chicken LR8B (8) and mouse ApoER2 (24) are described in the respective references.

Binding and Internalization of beta VLDL and alpha 2M* by Receptor-expressing Cells-- Rabbit beta VLDL was prepared from the plasma of animals fed a 2% cholesterol, 10% corn oil diet for 3 weeks (27) and was radiolabeled with 125I by the iodine monochloride method as described earlier (25). Lipoprotein concentration is expressed in terms of protein content that was measured by a modified Lowry procedure as described previously (28). alpha 2M was isolated from chicken plasma as described (29). Native alpha 2M was radiolabeled using Iodo-Gen pre-coated iodination tubes according to the manufacturer's recommendation (Pierce, catalog number 28601) to specific activities of 300-400 cpm/ng. Labeled alpha 2M-trypsin complexes (alpha 2M*) were generated as described (29). Complete activation of labeled alpha 2M by trypsin was monitored by native gel electrophoresis using the Tris borate system described by van Leuven (30). Recombinant human RAP was produced as a glutathione S-transferase (GST) fusion protein using a pGEX 2T-derived (Amersham Pharmacia Biotech) expression plasmid in DH5alpha bacteria (31).

Internalization of 125I-beta VLDL and 125I-alpha 2M* by LR8B-, ApoER2Delta 4-6-, and ApoER2Delta 4-6,8-expressing 293 cells was measured according to the standard protocol for uptake of LDL (32). In brief, 293 cells were cultured in poly-L-lysine-treated 3-cm dishes and grown to a 70% confluency. After three washes with phosphate-buffered saline, cells were incubated with Dulbecco's modified Eagle's medium containing 2% bovine serum albumin, 584 mg/liter glutamine, and 125I-labeled ligand at the indicated concentrations for 3 h at 37 °C. After washing, the cells were lysed by addition of 1 ml of 0.1 N NaOH and incubation at 23 °C for 10 min. The radioactivity in the lysate was determined with a gamma -counter (COBRA II, Packard Instrument Co.), and the protein concentration was determined. Kd values were determined by Scatchard analysis and expressed in nM using a Mr = 350.000 for beta VLDL.

Reelin Binding Studies-- 293 cells expressing ApoER2Delta 4-6 and ApoER2Delta 4-6,8 and mock-transfected cells were washed and resuspended in phosphate buffer and incubated with conditioned media from reelin-expressing 293T cells as described (15). In brief, 293T cells (60-80% confluent) were transfected with 7 µg of the reelin construct pCRL. The following day, the culture medium was replaced with a serum-reduced medium (Opti-MEM). After 2 more days the conditioned medium was collected and used for incubation of ApoER2-expressing cells. For ApoER2 expression, 293 cells were transiently transfected with 10 µg of ApoER2Delta 4-6 and ApoER2Delta 4-6,8 constructs. After 48 h the cells were harvested, washed once with 1 ml of phosphate-buffered saline, and incubated with 1 ml of the reelin supernatant at 4 °C for 4 h in the absence or presence of GST-RAP (30 µg/ml), EDTA (20 mM), or beta -VLDL (50 µg/ml). CaCl2 was added to a final concentration of 0.5 mM. The cells were washed 2× with 1.5 ml of phosphate-buffered saline and lysed with 50 µl buffer containing 50 mM Tris, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 20 mM sodium fluoride, 1 mM sodium orthovanadate, and proteinase inhibitors. After 30 min lysis on ice, the cell extracts were centrifuged at 13,000 × g for 30 min. 6-10 µl of the supernatant was loaded on a 7.5% gel. Transfer to nitrocellulose was done as described previously (16). The blot was incubated for 3 h with G10 antibody (provided by Dr. Andre Goffinet, Namur Med. School, Namur, Belgium) at a concentration of 1:1000. Goat anti-mouse HRP was used as a secondary antibody at a concentration of 1:10,000. The blots were developed using an ECL kit.

Alternatively, reelin binding to both splice variants of the receptor was tested by a cell-independent assay described by Hiesberger et al. (16). For this assay, cDNAs coding for the ligand binding domains of ApoER2Delta 4-6 and ApoER2Delta 4-6,8, respectively, were amplified by PCR using the respective full-length cDNAs as templates and fused to the constant human IgG domain as described (16) resulting in ApoER2Delta 4-6-Fc and ApoER2Delta 4-6,8-Fc. Recombinant fusion proteins were expressed in 293 cells, and the secreted proteins (1 ml of cell supernatant) were bound to protein-A Sepharose (30 µl slurry) as described. The protein-A Sepharose was then incubated with 500 µl of conditioned media from reelin-expressing 293T cells in the presence of 30 µg/ml RAP-GST or 20 mM EDTA or medium for 4 h at 4 °C. Detection of bound reelin was performed as described (16) using G10 as primary antibody and goat anti-mouse IgG conjugated to HRP as second antibody. The amounts of receptor-Fc fusion proteins present on the blot were analyzed by Western blotting using an HRP-coupled anti-V5 antibody (Invitrogen).

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

When we reported the cDNA cloning of chicken LR8B, we also presented the amino acid sequence derived from a partial cDNA for the corresponding murine homologue (4). The 5'-end of that cDNA defined the carboxyl-terminal part of the last LA-binding repeat of the mouse receptor. By using this sequence information for RT-PCR experiments, we were able to assign this sequence to repeat number 7 of a mouse variant of LR7/8B that lacks repeat 8 due to differential splicing (5). By using two rounds of 5'-RACE, we now have obtained the full-length cDNA for mouse ApoER2 (Fig. 1). As outlined below, the murine receptor appears to be a highly heterogeneous family of proteins due to multiple alternative splicing events. Therefore we refer to the murine protein as apoER2 as originally suggested for the human protein by Yamamoto and colleagues (6). According to the rule of Van Heijne (33), we assigned the cleavage site for the signal peptide to amino acids 28/29, producing a mature receptor in which the first LA repeat is 7 amino acids longer than that of human apoER2 and 8 amino acids longer than that of chicken LR7/8B. Surprisingly, the murine cDNA codes for a receptor harboring only 5 LA repeats. Upon computer-assisted sequence alignment (Geneworks) with human apoER2 and chicken LR8B, it became evident that repeats 4-6 are missing from this transcript. As reported recently, such a variant does exist for human ApoER2 (7). Furthermore, the cloned murine transcript contains the eighth repeat but not a 13-amino acid insertion that harbors a furin consensus cleavage site at its carboxyl-terminal end. Alternative transcripts containing such an insertion exist in man and mice but not in chicken (5).


View larger version (85K):
[in this window]
[in a new window]
 
Fig. 1.   Nucleotide and deduced amino acid sequence of the cDNA for murine ApoER2. Amino acid sequence numbering starts with the first amino acid in the mature protein after cleavage of the putative signal sequence. The sequence corresponding to the signal peptide is boxed. Cysteine residues are encircled. The transmembrane domain is underlined. The cytoplasmic internalization signal sequence is boxed.

Taken together, these results suggest that the ligand binding domain of murine apoER2 might be subject to multiple alternative splicing events producing a highly heterogeneous population of receptors. To evaluate this situation in mice in close detail, we characterized the splice variants in brain and placenta, the major sites of ApoER2 expression in the mouse by RT-PCR experiments using different sets of primers flanking the region between repeat 7 and the 5'-end of the EG repeats (Fig. 2, primers 1, 2) and flanking the cluster of repeats 4-6 (Fig. 2, primers 3, 4), respectively. As shown in Fig. 2a, in adult mouse brain 3 distinct variants are present. These transcripts contain in addition to repeats 1-3 the following: (i) either both repeats 7 and 8 (505 bp), (ii) only repeat 7 together with a 13-amino acid insertion defining a consensus furin cleavage site (421 bp), or (iii) repeat 7 only (382 bp). In embryonic brain (day 10), however, the large variant containing repeat 8 is completely missing. This variant appears at day 12 establishing a splice variant pattern indistinguishable from that seen in the adult brain (Fig. 2b). In mouse placenta a single amplicon with a size of 421 bp is present (Fig. 2a). Upon sequencing, this band turned out to be the transcript coding for the receptor variant containing the insertion with the furin site and lacking repeat 8. If the suggested cleavage at this site does occur, the corresponding placental protein could be a soluble receptor fragment with possibly different functions from those of the full-length variants present in the brain.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 2.   Analysis of splice variants in the ligand binding domain of mouse ApoER2 and chicken LR7/8B. mRNA from chicken and mouse brain and mouse placenta was used for cDNA synthesis with reverse transcriptase. The resulting cDNAs and DNA prepared from a mouse P1 clone was used for PCR amplification with the indicated primer combinations. Amplified products were separated on 1.5% agarose gels (a-c, mouse; d, chicken). The positions of the primers used are indicated by arrows in the schematic, highlighting the relevant structural features of the hypothetical cDNA deduced from the murine ApoER2 gene. Empty numbered boxes and shaded boxes represent sequences coding for LA repeats and EG repeats A and B, respectively.

By using a primer pair flanking repeats 4-6 (primers 3 and 4), the only amplicon obtained using mRNA either from adult brain or placenta had a length of 197 bp (Fig. 2c). Upon sequencing, it became evident that the amplified cDNA was identical to the corresponding region of the cDNA shown in Fig. 1 lacking repeats 4-6. As control we performed the same analysis with a chicken-specific primer pair using chicken brain mRNA as template. As seen in Fig. 2d, the only band obtained has a length of 614 bp and is derived from a transcript containing these 3 LA repeats. Since exactly these repeats are encoded for by a single exon in the human gene (7), we tested whether the corresponding exon was lost from the mouse gene or whether it is deleted from the transcripts by alternative splicing. Thus, we characterized the 5'-part of the murine apoER2 gene which codes for the ligand binding domain of the receptor. As depicted in Fig. 3A, the region of interest of the murine apoER2 gene was cloned by a combination of fragments of a P1 clone and of PCR-derived clones obtained by respective primers located in the indicated regions of the gene.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 3.   Organization of the 5'-region of the murine ApoER2 gene. A, the organization of the 5'-region of the murine ApoER2 gene is schematically shown. Exons are drawn as lines and introns as triangles. The intron numbers are shown on top. The exons are labeled with the designation of corresponding structural elements of the receptor. Below, P1-derived clones and PCR-derived clones covering the region of the gene are drawn as lines (combinations of numbers and letters refer to the primers described under "Materials and Methods"). The schematic and the clones are not drawn to scale. B, exon/intron organization of the murine ApoER2 gene. Intronic sequences are shown in lowercase letters, and exon sequences are in uppercase letters. The intron numbers refer to the numbers used in A. Consensus sequences for the 5'-splice donor and 3'-splice acceptor sites flanking exon 5 are underlined (see text). The corresponding human sequences in introns 4 and 5 are shown below the respective mouse sequences. C, nucleotide and deduced amino acid sequence of the cDNA encoded by exon 5 of the murine ApoER2 gene. Intronic sequences are shown in lowercase letters. Cysteine residues are encircled. Portions of codons interrupted by introns are underlined.

The apoER2 gene is organized much in the same way as that for human apoER2 (7). In particular, the exon encoding the putative LA repeats 4-6 is indeed present in the murine gene; the corresponding cDNA is shown in Fig. 3C. By having obtained the sequence coding for repeats 4-6 from genomic cloning, we were able to design another control experiment for the presence of transcripts containing this exon in brain and placenta, respectively. A primer combination corresponding to sequences within this exon (Fig. 2, primers 5 and 6) were used to amplify corresponding transcripts by RT-PCR. As seen in Fig. 2b, the expected amplicon with a size of 293 bp was only obtained using the P1 clone as template but not with cDNA derived from either brain or placental mRNA. This experiment clearly demonstrates that this exon is missing from transcripts in mice. It has been demonstrated that mutations in sequences near splice junctions can affect splicing efficiency (34). Thus, the flanking exon-intron junctions of exon 5 were compared with the consensus sequences for such regions (35). Both splice sites match the consensus in that the 5'-donor site contains the 5'-GT, which is essentially invariant, and the 3'-acceptor site contains a CAG which follows a pyrimidine-rich stretch at the 3'-end of the corresponding intron (the respective sequences are underlined in Fig. 3B). Furthermore, the respective intron sequences are completely conserved between the murine and the human gene (Fig. 3B). From the organization of the gene and the sequences of the respective exon/intron junctions, it is not obvious why this exon is spliced out constitutively from the mature transcripts in mice, but only facultatively in man (7). However, in a report where alternate splicing patterns of ApoER2 in normal and Alzheimer brains was investigated, the corresponding exon was missing in all human brain samples examined (10). To clarify the situation, we cloned a genomic fragment containing the exon coding for repeat 4-6 and parts of the upstream and downstream introns into the exon trap vector pet01 creating pEx4-6 (Fig. 4A). As internal control we combined this genomic fragment with another fragment harboring the exon coding for repeat 2 (pEx24-6). When transfected into 293 cells (Fig. 4B), pEx4-6 produced a transcript of 246 bp, indistinguishable from that produced by the vector alone. Sequencing of both products confirmed these bands to be derived from the intrinsic exons present in the vector. pEx2,4-6, however, produced a transcript with a length of 369 bp containing a hybrid cDNA made up of the exons present in the vector and the exon coding for repeat 2. The exon for repeats 4-6 again was missing from the transcript, indicating that this sequence is not recognized as exon in this system.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 4.   Exon trapping analysis of the exon corresponding to repeat 4-6. A, the organization of the exon trap constructs used in the experiment is schematically shown. pet01 is the original vector (MoBiTec) with a multiple cloning site within an intron flanked by two functional exons. For pEx4-6, genomic clone 5 was inserted into the multiple cloning site of pet01. pEx2,4-6 was created by inserting clone G14A13B3 5' of clone 5. B, 3 µg of DNA of pet01, pEx4-6, and pEx2,4-6 were transfected into 293 cells; after 48 h mRNA was reverse-transcribed, and the transcripts were analyzed by PCR as described under "Materials and Methods." PCR products derived from the respective transfection experiments are shown.

Another very interesting feature of the murine gene is the fact that the short insertion of 13 amino acids specifying a consensus furin cleavage site, present in some splice variants of ApoER2 (5), is encoded by a separate small exon and is not inserted by the use of an alternative 5'-splice donor site, as might be expected for such a small insertion. The 39-bp exon is located between those for LA repeat 8 and EG repeat A, respectively (Fig. 5). Sequence details of this region are shown in Fig. 5. Since a homologous insertion is also present in variants of human ApoER2 (5), we assume that in the human gene a corresponding exon is present in intron 6 (numbering according to Ref. 7).


View larger version (9K):
[in this window]
[in a new window]
 
Fig. 5.   Partial sequence of the region of the murine ApoER2 gene coding for the furin cleavage site. Nucleotide sequence and deduced amino acid sequences of splice variants derived thereof are represented in relation to a schematic representing structural elements of the murine ApoER2 protein. Localization of introns are highlighted by filled rectangles. Intronic sequences are shown in lowercase letters and exon sequences in uppercase letters. The putative furin cleavage consensus sequence is underlined. Empty numbered boxes and shaded boxes represent LA repeats and ER repeats A, respectively.

To determine if the constitutive loss of repeats 4-6 in the murine receptor which leads to the expression of receptor variants with either 4 or 5 ligand binding repeats results in distinct ligand specificity, we expressed these variants, ApoER2Delta 4-6 and ApoER2Delta 4-6,8, in 293 cells, measured their affinities for beta VLDL and alpha 2M (alpha 2M*), and compared the results with those obtained with the chicken variant containing the maximum of 8 ligand binding repeats (LR8B). The inset in Fig. 6D represents a Western blot with membrane detergent extracts from 293 cells expressing murine ApoER2Delta 4-6,8 (lane 1), ApoER2Delta 4-6 (lane 2), and chicken LR8B (lane 3), respectively. Double bands seen for the murine proteins most likely result from differential glycosylation in this cell system. To test for the ability of these receptors to interact with ligands, we used a combined binding and internalization assay (8). As demonstrated in Fig. 6, A-C, all three receptor variants bind beta VLDL with high affinity (Kd value of 53 nM for ApoER2Delta 4-6,8; Kd value of 13 nM for ApoER2Delta 4-6; and Kd value of 8 nM for LR8B). This is not surprising, since a human variant of ApoER2 harboring only 3 binding repeats has been already shown to bind beta VLDL efficiently (7). Apparently, the affinity for beta VLDL slightly decreases with the successive loss of binding repeats. However, it was very interesting to note that neither mouse ApoER2Delta 4-6,8 nor ApoER2Delta 4-6 bind alpha 2M* (Fig. 6, D and E), in sharp contrast to LR8B which binds alpha 2M* with high affinity (Kd value of 129 nM) (Fig. 6F, and cf. (8)). The small amount of beta VLDL and alpha 2M* binding to mock-transfected 293 cells is most likely due to low expression of intrinsic LDLR-related protein by these cells (8). From an evolutionary point of view, it is interesting that the loss of 3 binding repeats by constitutive splicing of the corresponding exon in mice compromises the ability of the receptor to bind alpha 2M*. Apparently, a minimum of 8 ligand binding repeats seems necessary for recognition of alpha 2M*, as suggested by the fact that the chicken homologue of the VLDLR, i.e. LR8, contains 8 ligand binding repeats and binds alpha 2M* with high affinity (8), whereas the LDLR harboring seven repeats does not.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 6.   Binding and internalization of alpha 2M* and beta VLDL in cells expressing ApoER2Delta 4-6, ApoER2Delta 4-6,8, or LR8B. 293 cells expressing ApoER2Delta 4-6,8 (A and D), ApoER2Delta 4-6 (B and E), or LR8B (C and F) and 293-cells transfected with the empty plasmid were incubated for 3 h at 37 °C with the indicated concentration of 125I-labeled beta VLDL (A-C) or alpha 2M* (D-F). Cell associated activity (surface-bound and internalized) was measured as described under "Materials and Methods." Values were corrected for non-saturable binding and uptake in the presence of a 40-fold molar excess of unlabeled beta VLDL or human recombinant RAP. Values are averages of duplicate determinations, and Scatchard analysis was performed to determine the indicated Kd values. D, inset, Western blot analysis of 293 cells expressing ApoER2Delta 4-6,8 (lane 1), ApoER2Delta 4-6 (lane 2), and LR8B (lane 3), respectively. Triton X-100 detergent extracts (50 µg of protein/lane) from transfected 293 cells were subjected to electrophoresis under reducing conditions on a 4.5-18% SDS-polyacrylamide gel. Proteins were transferred to a nitrocellulose membrane that was incubated with antibodies specific for the respective proteins (20 µg/ml). Bound IgG was visualized with protein A-HRP (1 µg/ml) and a chemiluminescence system.

Since it has recently been shown that one of the murine variants (ApoER2Delta 4-6) acts as receptor for reelin (15, 16), and as demonstrated here (Fig. 7, A and B), expression of the 4-repeat and 5-repeat variants in the mouse brain is highly regulated during embryonic development, we determined and compared reelin binding to both receptor variants. Reelin binding was measured with two independent approaches, one using receptor-expressing cells (15) and the other using soluble receptor constructs as described recently (16). As demonstrated in Fig. 7A, cells expressing either ApoER2Delta 4-6,8 or ApoER2Delta 4-6 bind equal amounts of reelin produced by transfected 293T cells. Binding of reelin to both receptor variants is abolished by EDTA, GST-RAP, and beta VLDL. This result was confirmed by the second assay showing that soluble ApoER2 receptor constructs harboring either 4 or 5 binding repeats bind reelin with equal affinities (Fig. 7B). Again, binding is completely abolished by an excess of GST-RAP or by EDTA.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 7.   Reelin binding to ApoER2 variants. A, 293 cells expressing ApoER2Delta 4-6,8 or ApoER2Delta 4-6 and 293 cells transfected with the empty plasmid were harvested and incubated with 1 ml of conditioned medium from reelin producing 293T cells as described under "Materials and Methods." Incubations were carried out without any addition or in the presence of GST-RAP (30 µg/ml), EDTA (20 mM), or beta -VLDL (50 µg/ml). After incubation the cells were extensively washed, and bound reelin was detected by lysis of the cells and subsequent Western blot analysis using a specific antibody against reelin (G10). B, recombinant fusion proteins containing the ligand binding domains of ApoER2Delta 4-6,8, ApoER2Delta 4-6, or LDL receptor and the constant domain of human IgG from 1 ml of culture supernatants from 293 cells expressing ApoER2Delta 4-6-Fc, ApoER2Delta 4-6,8-Fc, or LDLR-Fc were bound to protein A-Sepharose. The protein A-Sepharose was then incubated with conditioned media from reelin expressing 293T cells in the presence of 30 µg/ml RAP-GST, 20 mM EDTA, or medium. Bound reelin was detected by Western blot analysis using G10 as primary antibody and goat anti-mouse IgG conjugated to HRP as second antibody. To test for comparable amounts of fusion proteins present in the assay, the filter was stripped and re-probed with an anti-V5 antibody.

The complex situation is summarized in Fig. 8, which compiles all identified transcripts exhibiting variations in the ligand binding domain of the receptor in different species. In chicken, where the prevalent expression of LR7/8B occurs in brain, only two distinct variants harboring 7 or 8 repeats exist. As analyzed at the mRNA level, the furin cleavage site, which exists in man and mouse, is obviously absent. However, the corresponding region of the chicken gene has not been characterized to date, and it may well be that this exon is constitutively spliced out in chicken transcripts. Therefore, the question whether the corresponding exon in mammals was gained during evolution cannot be answered yet. The mouse, as documented here, produces three major transcripts varying in the ligand binding domain. There are two significant differences to the transcripts in chicken. First, none of the transcripts found contained repeats 4-6, which are present on a single exon (exon 5). Genomic analysis suggests that this exon is constitutively deleted by splicing out in mice. Second, in mice there is an additional small exon following that for LA repeat 8, giving rise to a variant harboring a furin consensus cleavage site at the carboxyl-terminal end of the ligand binding domain. Most interestingly, this variant is the only one detectable in placenta, showing that some of the splice events are tissue-specific.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 8.   Comparison of the organization of the 5'-region of the mouse and the human ApoER2 genes and transcripts derived from differential splicing in man, mouse, and chicken. Boxes in the schematic represent exons within the respective genes and transcripts. Numbers in the boxes refer to the numbers of the LA repeats of the corresponding proteins. Introns are shown as inverted filled triangles and are numbered consecutively; unknown elements are indicated by ?. The exons coding for the insertion containing the furin cleavage site are labeled with the consensus sequence (RRPR and RHPR). Shaded boxes represent EG repeats A. Previously published information is indicated by the respective references.

The situation in man is not as clear yet. Obviously, none of the characterized transcripts contain repeat 8, and analysis of the human gene suggests that the corresponding exon might have been lost (6, 7). However, this exon seems to be present in the human gene, but a mutation in the 5'-splice donor site causes this exon to be constitutively skipped (36). In analogy to the mouse gene, a corresponding exon coding for the furin-cleavage site insertion (5) is likely present in the corresponding region of the human gene. In addition to the mouse variants described herein, a receptor transcript containing only repeats 1-3 has been reported to be present in humans (7). As mentioned above, the use of exon 5, coding for repeats 4-6, could not be confirmed in a recent study on normal and Alzheimer brains (10).

So far, it has been shown that all human splice variants are able to bind rabbit beta -VLDL with similar affinity (6, 7). Thus, it is not surprising that both murine ApoER2Delta 4-6 and ApoER2Delta 4-6,8 bind beta -VLDL with high affinity. However, the fact that mouse ApoER2 does not bind alpha 2M* is interesting from an evolutionary point of view considering that the chicken homologue recognizes alpha 2M*. From a structural point of view the lack of alpha 2M* binding to mouse ApoER2 is not surprising, since the alpha 2M*-receptors found so far harbor a minimum of 8 ligand binding repeats clustered in one domain (LDLR-related protein, chicken LR8, chicken LR8B). Apparently, ApoER2 has lost its ability to bind alpha 2M* but has gained other features during evolution from birds to mammals. These features include the potential to be produced as a soluble receptor fragment, and the ability to interact with certain intracellular adapter proteins like JIP-1 and JIP-2, mediated by an insertion in the cytoplasmic tail of the receptor (24).

Furthermore, this study demonstrates for the first time that both murine ApoER2 variants containing either 4 or 5 LA repeats bind reelin equally well. By taking into account that the expression of the variants is highly regulated during brain development, it might be possible that other ligands exist in the brain which discriminate between both ApoER2 variants modulating the reelin response or mediating a reelin-independent signal.

If indeed the arrangement of LA repeats in LDLR relatives defines their ligand binding specificity, the splicing events in the lr7/8B and ApoER2 gene might result in a complex functional pattern of its products in different species and organs.

    ACKNOWLEDGEMENTS

We appreciate the technical assistance of Harald Rumpler and Robert Wandl. We thank Dr. Andre Goffinet for the gift of the anti-reelin antibody G10 and Dr. Tom Curran for the reelin expression plasmid.

    FOOTNOTES

* This work was supported by the Austrian Science Foundation Grants P13931-MOB and F606 (to J. N.) and P13940-MOB (to W. J. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AJ312058 and AJ312059.

To whom correspondence should be addressed: Institute of Medical Biochemistry, Dept. of Molecular Genetics, Biocenter and University of Vienna, Dr. Bohrgasse 9/II, A-1030 Vienna, Austria. Tel.: 43-1-4277-61808; Fax: 43-1-4277-9618; E-mail: JNIMPF@mol.univie.ac.at.

Published, JBC Papers in Press, April 6, 2001, DOI 10.1074/jbc.M102662200

    ABBREVIATIONS

The abbreviations used are: LDLR, low density lipoprotein receptor; VLDLR, very LDLR; apo, apolipoprotein; LR7/8B, LDLR relative with 7 or 8 LA repeats; ApoER2, apoE receptor 2; RAP, receptor-associated protein; alpha 2M, alpha 2-macroglobulin; PCR, polymerase chain reaction; LA, type A binding repeats; EG, type B repeats; RT, reverse transcriptase; bp, base pair; RACE, rapid amplification of cDNA ends; HRP, horseradish peroxidase; GST, glutathione S-transferase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

1. Schneider, W. J., Nimpf, J., and Bujo, H. (1997) Curr. Opin. Lipidol. 8, 315-319[Medline] [Order article via Infotrieve]
2. Schneider, W. J., and Nimpf, J. (1993) Curr. Opin. Lipidol. 4, 205-209
3. Schneider, W. J. (1989) Biochim. Biophys. Acta 988, 303-317[Medline] [Order article via Infotrieve]
4. Novak, S., Hiesberger, T., Schneider, W. J., and Nimpf, J. (1996) J. Biol. Chem. 271, 11732-11736[Abstract/Free Full Text]
5. Brandes, C., Novak, S., Stockinger, W., Herz, J., Schneider, W. J., and Nimpf, J. (1997) Genomics 42, 185-191[CrossRef][Medline] [Order article via Infotrieve]
6. Kim, D.-H., Iijima, H., Goto, K., Sakai, J., Ishii, H., Kim, H.-J., Suzuki, H., Kondo, H., Saeki, S., and Yamamoto, T. (1996) J. Biol. Chem. 271, 8373-8380[Abstract/Free Full Text]
7. Kim, D.-H., Magoori, K., Inoue, T. R., Mao, C. C., Kim, H.-J., Suzuki, H., Fujita, T., Endo, Y., Saeki, S., and Yamamoto, T. T. (1997) J. Biol. Chem. 272, 8498-8504[Abstract/Free Full Text]
8. Stockinger, W., Hengstschläger-Ottnad, E., Novak, S., Matus, A., Hüttinger, M., Bauer, J., Lassmann, H., Schneider, W. J., and Nimpf, J. (1998) J. Biol. Chem. 273, 32213-32221[Abstract/Free Full Text]
9. Strittmatter, W. J., and Roses, A. D. (1996) Annu. Rev. Neurosci. 19, 53-77[CrossRef][Medline] [Order article via Infotrieve]
10. Clatworthy, A. E., Stockinger, W., Christie, R. H., Schneider, W. J., Nimpf, J., Hyman, B. T., and Rebeck, G. W. (1999) Neuroscience 90, 903-911[CrossRef][Medline] [Order article via Infotrieve]
11. Trommsdorff, M., Gotthardt, M., Hiesberger, T., Shelton, J., Stockinger, W., Nimpf, J., Hammer, R., Richardson, J. A., and Herz, J. (1999) Cell 97, 689-701[Medline] [Order article via Infotrieve]
12. Cooper, J. A., and Howell, B. W. (1999) Cell 97, 671-674[Medline] [Order article via Infotrieve]
13. Curran, T., and D'Arcangelo, G. (1998) Brain Res. Rev. 26, 285-294[CrossRef][Medline] [Order article via Infotrieve]
14. Walsh, C. A., and Goffinet, A. M. (2000) Curr. Opin. Genet. & Dev. 10, 270-274[CrossRef][Medline] [Order article via Infotrieve]
15. D'Arcangelo, G., Homayoundi, R., Keshvara, L., Rice, D. S., Sheldon, M., and Curran, T. (1999) Neuron 24, 471-479[Medline] [Order article via Infotrieve]
16. Hiesberger, T., Trommsdorff, M., Howell, B. W., Goffinet, A., Mumby, M. C., Cooper, J. A., and Herz, J. (1999) Neuron 24, 481-489[Medline] [Order article via Infotrieve]
17. Senzaki, K., Ogawa, M., and Yagi, T. (1999) Cell 99, 635-647[Medline] [Order article via Infotrieve]
18. Dulabon, L., Olson, E. C., Taglienti, M. G., Eisenhuth, S., McGrath, B., Walsh, C. A., Kreidberg, J. A., and Anton, E. S. (2000) Neuron 27, 33-44[Medline] [Order article via Infotrieve]
19. Howell, B. W., Lanier, L. M., Frank, R., Gertler, F. B., and Cooper, J. A. (1999) Mol. Cell. Biol. 19, 5179-5188[Abstract/Free Full Text]
20. Trommsdorff, M., Borg, J.-P., Margolis, B., and Herz, J. (1998) J. Biol. Chem. 273, 33556-33565[Abstract/Free Full Text]
21. Howell, B. W., Herrick, T. M., and Cooper, J. A. (1999) Genes Dev. 13, 643-648[Abstract/Free Full Text]
22. Howell, B. W., Herrick, T. M., Hildebrand, J. D., Zhang, Y., and Cooper, J. A. (2000) Curr. Biol. 10, 877-885[CrossRef][Medline] [Order article via Infotrieve]
23. Gotthardt, M., Trommsdorff, M., Nevitt, M. F., Shelton, J., Richardson, J. A., Stockinger, W., Nimpf, J., and Herz, J. (2000) J. Biol. Chem. 275, 25616-25624[Abstract/Free Full Text]
24. Stockinger, W., Brandes, C., Fasching, D., Hermann, M., Gotthardt, M., Herz, J., Schneider, W. J., and Nimpf, J. (2000) J. Biol. Chem. 275, 25625-25632[Abstract/Free Full Text]
25. Hayashi, K., Nimpf, J., and Schneider, W. J. (1989) J. Biol. Chem. 264, 3131-3139[Abstract/Free Full Text]
26. Hiesberger, T., Hermann, M., Jacobsen, L., Novak, S., Hodits, R. A., Bujo, H., Meilinger, M., Hüttinger, M., Schneider, W. J., and Nimpf, J. (1995) J. Biol. Chem. 270, 18219-18226[Abstract/Free Full Text]
27. Kovanen, P. T., Brown, M. S., Basu, S. K., Bilheimer, D. W., and Goldstein, J. L. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 1396-1400[Abstract]
28. Schneider, W. J., Goldstein, J. L., and Brown, M. S. (1980) J. Biol. Chem. 255, 11442-11447[Abstract/Free Full Text]
29. Jacobsen, L., Hermann, M., Vieira, P. M., Schneider, W. J., and Nimpf, J. (1995) J. Biol. Chem. 270, 6468-6475[Abstract/Free Full Text]
30. Leuven, F. V., Cassiman, J. J., and Berge, H. V. D. (1981) J. Biol. Chem. 256, 9016-9022[Free Full Text]
31. Herz, J., Goldstein, J. L., Strickland, D. K., Ho, Y. K., and Brown, M. S. (1991) J. Biol. Chem. 266, 21232-21238[Abstract/Free Full Text]
32. Goldstein, J. L., Basu, S. K., and Brown, M. S. (1983) Methods Enzymol. 98, 241-259[Medline] [Order article via Infotrieve]
33. Heijne, G. V. (1983) Eur. J. Biochem. 133, 17-21[Abstract]
34. MacLachlan, I., Nimpf, J., White, H. B., and Schneider, W. J. (1993) J. Biol. Chem. 268, 23222-23226[Abstract/Free Full Text]
35. Senapathy, P., Shapiro, M. B., and Harris, N. L. (1990) in Molecular Evolution: Computer Analysis of Protein and Nucleic Acid Sequences (Doolittle, R. F., ed) , p. 183, Academic Press Inc., San Diego
36. Kim, H.-J., Kim, D.-H., Magoori, K., Saeki, S., and Yamamoto, T. T. (1998) J. Biochem. (Tokyo) 124, 451-456[Abstract]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.